West Pharma (WST) Tops Q3 EPS by 26c

West Pharma (NYSE: WST) reported Q3 EPS of $2.06, $0.26 better than the analyst estimate of $1.80. Revenue for the quarter came in at $706.5 million versus the consensus estimate of $687.09 million.

GUIDANCE:

West Pharma sees FY2021 EPS of $8.40-$8.50, versus the consensus of $8.21. West Pharma sees FY2021 revenue of $2.8-2.81 billion, versus the consensus of $2.8 billion.

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance
• Taylor Devices (TAYD) Misses Q4 EPS by 31c